• 제목/요약/키워드: hepatic secretion

검색결과 74건 처리시간 0.028초

Computer Simulation of Glucose-insulin Kinetics During Intravenous Glucose Tolerance Test

  • Min, B.G;Woo, E.J.
    • 대한의용생체공학회:의공학회지
    • /
    • 제4권1호
    • /
    • pp.9-14
    • /
    • 1983
  • A new quantitative method was developed for separation of three interactive physiological factors (hepatic glucose balance, peripheral tissue's insulin resistivity, and insulin secretion rate) influencing glucose intolerance in diabetic mellitus using an equivalent circuit model and the intravenous glucose tolerance test (IVGTT) in six dogs and twenty two humans. The results show that the estimated model parameters of the above three factors are useful for evaluating different glucose-insulin kinetics in normal and diabetic subjects.

  • PDF

Myeloid-specific SIRT1 Deletion Aggravates Hepatic Inflammation and Steatosis in High-fat Diet-fed Mice

  • Kim, Kyung Eun;Kim, Hwajin;Heo, Rok Won;Shi, Hyun Joo;Yi, Chin-ok;Lee, Dong Hoon;Kim, Hyun Joon;Kang, Sang Soo;Cho, Gyeong Jae;Choi, Wan Sung;Roh, Gu Seob
    • The Korean Journal of Physiology and Pharmacology
    • /
    • 제19권5호
    • /
    • pp.451-460
    • /
    • 2015
  • Sirtuin 1 (SIRT1) is a mammalian $NAD^+$-dependent protein deacetylase that regulates cellular metabolism and inflammatory response. The organ-specific deletion of SIRT1 induces local inflammation and insulin resistance in dietary and genetic obesity. Macrophage-mediated inflammation contributes to insulin resistance and metabolic syndrome, however, the macrophage-specific SIRT1 function in the context of obesity is largely unknown. C57/BL6 wild type (WT) or myeloid-specific SIRT1 knockout (KO) mice were fed a high-fat diet (HFD) or normal diet (ND) for 12 weeks. Metabolic parameters and markers of hepatic steatosis and inflammation in liver were compared in WT and KO mice. SIRT1 deletion enhanced HFD-induced changes on body and liver weight gain, and increased glucose and insulin resistance. In liver, SIRT1 deletion increased the acetylation, and enhanced HFD-induced nuclear translocation of nuclear factor kappa B (NF-${\kappa}B$), hepatic inflammation and macrophage infiltration. HFD-fed KO mice showed severe hepatic steatosis by activating lipogenic pathway through sterol regulatory element-binding protein 1 (SREBP-1), and hepatic fibrogenesis, as indicated by induction of connective tissue growth factor (CTGF), alpha-smooth muscle actin (${\alpha}$-SMA), and collagen secretion. Myeloid-specific deletion of SIRT1 stimulates obesity-induced inflammation and increases the risk of hepatic fibrosis. Targeted induction of macrophage SIRT1 may be a good therapy for alleviating inflammation-associated metabolic syndrome.

Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression

  • Zhou, Da;Chen, Yuan-Wen;Zhao, Ze-Hua;Yang, Rui-Xu;Xin, Feng-Zhi;Liu, Xiao-Lin;Pan, Qin;Zhou, Huiping;Fan, Jian-Gao
    • Experimental and Molecular Medicine
    • /
    • 제50권12호
    • /
    • pp.2.1-2.12
    • /
    • 2018
  • Glucagon-like peptide-1 (GLP-1) has a broad spectrum of biological activity by regulating metabolic processes via both the direct activation of the class B family of G protein-coupled receptors and indirect nonreceptor-mediated pathways. GLP-1 receptor (GLP-1R) agonists have significant therapeutic effects on non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) in animal models. However, clinical studies indicated that GLP-1 treatment had little effect on hepatic steatosis in some NAFLD patients, suggesting that GLP-1 resistance may occur in these patients. It is well-known that the gut metabolite sodium butyrate (NaB) could promote GLP-1 secretion from intestinal L cells. However, it is unclear whether NaB improves hepatic GLP-1 responsiveness in NAFLD. In the current study, we showed that the serum GLP-1 levels of NAFLD patients were similar to those of normal controls, but hepatic GLP-1R expression was significantly downregulated in NAFLD patients. Similarly, in the NAFLD mouse model, mice fed with a high-fat diet showed reduced hepatic GLP-1R expression, which was reversed by NaB treatment and accompanied by markedly alleviated liver steatosis. In addition, NaB treatment also upregulated the hepatic p-AMPK/p-ACC and insulin receptor/insulin receptor substrate-1 expression levels. Furthermore, NaB-enhanced GLP-1R expression in HepG2 cells by inhibiting histone deacetylase-2 independent of GPR43/GPR109a. These results indicate that NaB is able to prevent the progression of NAFL to NASH via promoting hepatic GLP-1R expression. NaB is a GLP-1 sensitizer and represents a potential therapeutic adjuvant to prevent NAFL progression to NASH.

사람의 눈지방유래 줄기세포의 간세포 분화 (Hepatic Differentiation of Human Eyelid Adipose-Derived Stem Cells)

  • 박수연;박세아;강현미;김해권
    • 한국발생생물학회지:발생과생식
    • /
    • 제12권2호
    • /
    • pp.183-194
    • /
    • 2008
  • A variety of stem cells has been emerging as therapeutic cells that can replace organ transplantation in human liver diseases. The present study focused on whether human eyelid adipose-derived stem cells (HAD) might differentiate into functional hepatocyte-like cells in vitro. HAD were isolated from human eyelid adipose tissue. Effect of dimethyl sulfoxide (DMSO), fibroblast growth factor (FGF)-2 and FGF-4 on the hepatic differentiation of HAD have been examined in vitro. Immunocytochemical analysis and PAS staining showed that HAD cultured in both DMSO and FGF-4 exhibited the most intense staining than HAD of the other experimental groups. These HAD expressed numerous hepatocyte-related genes. Immunoblotting analyses showed that HAD cultured in the presence of DMSO and FGF-4 secreted higher amount of human albumin than HAD cultured in other conditions. Urea analysis also demonstrated that these HAD produced higher amount of urea than any other groups of HAD. In conclusion, combined treatment of DMSO and FGF-4 could effectively induce the functional differentiation of HAD into hepatocyte-like cells.

  • PDF

The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities

  • Erion, Derek M.;Park, Hyun-Jun;Lee, Hui-Young
    • BMB Reports
    • /
    • 제49권3호
    • /
    • pp.139-148
    • /
    • 2016
  • In the past decade, the incidence of type 2 diabetes (T2D) has rapidly increased, along with the associated cardiovascular complications. Therefore, understanding the pathophysiology underlying T2D, the associated complications and the impact of therapeutics on the T2D development has critical importance for current and future therapeutics. The prevailing feature of T2D is hyperglycemia due to excessive hepatic glucose production, insulin resistance, and insufficient secretion of insulin by the pancreas. These contribute to increased fatty acid influx into the liver and muscle causing accumulation of lipid metabolites. These lipid metabolites cause dyslipidemia and non-alcoholic fatty liver disease, which ultimately contributes to the increased cardiovascular risk in T2D. Therefore, understanding the mechanisms of hepatic insulin resistance and the specific role of liver lipids is critical in selecting and designing the most effective therapeutics for T2D and the associated co-morbidities, including dyslipidemia and cardiovascular disease. Herein, we review the effects and molecular mechanisms of conventional anti-hyperglycemic and lipid-lowering drugs on glucose and lipid metabolism.

Determination of Optimum Aggregates of Porcine Hepatocytes As a Cell Source of a Bioartificial Liver

  • Lee, Doo-Hoon;Lee, Ji-Hyun;Choi, Jeong-Eun;Kim, Young-Jin;Kim, Sung-Koo;Park, Jung-Keug
    • Journal of Microbiology and Biotechnology
    • /
    • 제12권5호
    • /
    • pp.735-739
    • /
    • 2002
  • Large quantities of porcine hepatocyte aggregates with various degrees of aggregation (DA) could be obtained by controlling the suspension periods (0,9,24, and 48 h), and by entrapping the hepatocyte aggregates in model materials of encapsulation such as Ca-alginate and type-I collagen gels. The effects of DA on liver-specific functions of hepatocytes were evaluated in order to obtain optimum DA for the cell source of bioartificial liver (BAL) systems. Irregular rugged aggregates (size $75 \pm 28$ $\mu\textrm{m}$) farmed by 24 h of suspension culturing showed peak viability and hepatic functions such as ammonia removal and albumin secretion in the two types of entrapment systems, thus offering themselves as a stable cell source of a BAL system for hepatic functions and scale-up.

Necroptosis Is a Mechanism of Death in Mouse Induced Hepatocyte-Like Cells Reprogrammed from Mouse Embryonic Fibroblasts

  • Lee, Yun-Suk;Park, Kyung-Mee;Yu, Lina;Kwak, Ho-Hyun;Na, Hee-Jun;Kang, Kyung-Sun;Woo, Heung-Myong
    • Molecules and Cells
    • /
    • 제41권7호
    • /
    • pp.639-645
    • /
    • 2018
  • Liver transplantation is recommended for patients with liver failure, but liver donors are limited. This necessitates the development of artificial livers, and hepatocytes are necessary to develop such artificial livers. Although induced hepatocyte-like cells are used in artificial livers, the characteristics of mouse induced hepatocyte-like cells (miHeps) reprogrammed with embryonic fibroblasts have not yet been clarified. Therefore, this study investigated the mechanisms underlying the survival, function, and death of miHeps. miHeps showed decreased cell viability, increased cytotoxicity, decreased hepatic function, and albumin and urea secretion at passage 14. Addition of necrostatin-1 (NEC-1) to miHeps inhibited necrosome formation and reactive oxygen species generation and increased cell survival. However, NEC-1 did not affect the hepatic function of miHeps. These results provide a basis for development of artificial livers using hepatocytes.

Physiological Pharmacokinetic Model of Ceftriaxone Disposition in the Rat and the Effect of Caffeine on the Model

  • Kwon, Kwang-Il;Bourne, David-W.A.
    • Archives of Pharmacal Research
    • /
    • 제13권3호
    • /
    • pp.227-232
    • /
    • 1990
  • A Physiologically based pharmacokinetic model was used to describe the distribition and elimination of cefriazone in the rat. To validate the practical application of the model, the effect of cffeine on the model was also examined. The model consisted of eleven compartments representing the major sites for ceftriaxone distribution including carcass which served as a residual compartment. Elimination was represented by renal and hepatic (metabolic biliary )excretion with GI secretion and re-absorption. The drug concentrations in most of the tissues were simulated using flow limited equations while brain levels were simulated using membrane limited passive diffusion distribution. The experimental data were obtained by averaging the concentration of drug in the plasma and tissues of five rats after i. v. injection of cefriazone 100 mg/kg without and with caffeine 20 mg/kg. The data for the amount of ceftriazone excreted in urine and gut contents were used to apportion total body clearance. HPLC with UV detection was used for the assay with 0.1-0.2 $\mu$g/ml sensitivity. The great majority of drug concentrations with and without caffeine show reasonably good agreements to the simulation results within 20%. The effect of caffeine on renal and hepatic clearances was apparent with 18.8% and 18.6% increase in the model values, respectively.

  • PDF

마황 추출물의 in vitro 간세포 염증반응 유도 (In vitro hepatocyte inflammation by Ephedra sinica extracts)

  • 김일낭
    • 한국식품과학회지
    • /
    • 제51권1호
    • /
    • pp.24-28
    • /
    • 2019
  • 본 연구에서는 마황 70% 에탄올 추출물을 HepG2 세포에 $0.001-100{\mu}g/mL$의 농도로 처리하여 세포사멸, 사이토카인 분비, 세포 내 지방 축적 정도를 측정함으로써 마황의 간독성 기전을 in vitro 실험을 통해 살펴보았다. 마황 추출물 처리에 의해 $5-100{\mu}g/mL$의 농도에서 세포 사멸이 관찰되었다(p<0.05). 마황 추출물 처리에 의해 염증성 사이토카인인 IL-8과 M-CSF의 분비가 각각 0.05-100, $0.5-100{\mu}g/mL$의 농도에서 유의적으로 촉진되었으며, 세포 내 지방 축적은 $0.01-100{\mu}g/mL$의 처리 농도에서 유의적으로 증가하였다(p<0.05). 본 실험에서 마황 추출물은 IL-8 및 M-CSF와 같은 염증성 사이토카인의 분비를 촉진시키고, 간세포에 지방을 축적시킴으로써 간세포에 염증을 유발하는 것으로 나타났다. 이러한 형태의 간독성은 세포 사멸과 같은 심각한 독성을 유발하는 농도보다 10-500배 낮은 농도에서 관찰되어 저농도의 마황섭취에 의해 간염과 같은 간독성이 유발될 수 있음을 시사한다.

Supplementation of a Novel Microbial Biopolymer, PGB1, from New Enterobacter sp. BL-2 Delays the Deterioration of Type 2 Diabetic Mice

  • Yeo, Ji-Young;Lee, Yong-Hyun;Jeon, Seon-Min;Jung, Un-Ju;Lee, Mi-Kyung;Jung, Young-Mi;Choi, Myung-Sook
    • Journal of Microbiology and Biotechnology
    • /
    • 제17권12호
    • /
    • pp.1983-1990
    • /
    • 2007
  • Antidiabetic effects of a novel microbial biopolymer (PGB) 1 excreted from new Enterobacter sp. BL-2 were tested in the db/db mice. The animals were divided into normal control, rosiglitazone (0.005%, wt/wt), low PGB1 (0.1%, wt/wt), and high PGB1 (0.25%, wt/wt) groups. After 5 weeks, the blood glucose levels of high PGB1 and rosiglitazone supplemented groups were significantly lower than those of the control group. In hepatic glucose metabolic enzyme activities, the glucokinase activities of PGB1 supplemented groups were significantly higher than the control group, whereas the PEPCK activities were significantly lower. The plasma insulin and hepatic glycogen levels of the low and high PGB1 supplemented groups were significantly higher compared with the control group. Specifically, the insulin and glycogen increases were dose-responsive to PGB1 supplement. PGB1 supplement did not affect the IPGTT and IPITT compared with the control group; however, rosiglitazone significantly improved IPITT. High PGB1 and rosiglitazone supplementation preserved the appearance of islets and insulin-positive cells in immunohistochemical photographs of the pancreas compared with the control group. These results demonstrated that high PGB1 (0.25% in the diet) supplementation seemingly contributes to preventing the onset and progression of type 2 diabetes by stimulating insulin secretion and enhancing the hepatic glucose metabolic enzyme activities.